Abstract: The present disclosure relates to a communication method and system for converging a 5th-Generation (5G) communication system for supporting higher data rates beyond a 4th-Generation (4G) system with a technology for Internet of Things (IoT). The present disclosure may be applied to intelligent services based on the 5G communication technology and the IoT-related technology, such as smart home, smart building, smart city, smart car, connected car, health care, digital education, smart retail, security and safety services. A method performed by a first node is provided, comprising determining whether direct data forwarding between a third node and a second node is available, performing direct data forwarding if the direct data forwarding is available, otherwise, performing indirect data forwarding.

Abstract: A lighting device (1) is disclosed comprising a transmissive housing (3) and a filament (10) within said transmissive housing. The filament comprises a transmissive substrate (20) carrying a plurality of solid state lighting elements (30) and a phosphor containing resin coating (40) enveloping said filament. The resin coating includes at least one region (42) leaking light produced by said solid state lighting elements that is unconverted by said phosphor and the transmissive housing carries a further phosphor layer (7) covering part of the transmissive housing for each of said regions of the resin coating, each of said further phosphor layers being arranged to receive said unconverted light leaking from at least one of said regions. Also disclosed is a method of manufacturing such a lighting device.

Abstract: The present invention provides a polypeptide derivative, or a modified derivative or salt thereof, and use of the polypeptide derivative, or the modified derivative or salt thereof. The polypeptide derivative, or the modified derivative or salt thereof comprises a polypeptide having the sequence of the following general formula I: general formula I: HX2QGTFTSDX10SKYLX15EX17X18AX20X21FX23AWLEX28X29X30, wherein the definitions of X2, X10, X15, X17, X18, X20, X21, X23, X28, X29, and X30 are consistent with those in the claims and description. The polypeptide derivatives of the present invention are dual agonists for GC/GLP-1 receptor, have a synergic effect on energy metabolism, can effectively reduce weight and improve a body fat level while reducing blood glucose, and have a potential application value in the field of treatment of metabolic diseases such as diabetes and obesity.

Abstract: The present invention provides a compound having a structure of formula (I), a preparation method and use thereof, and a pharmaceutical composition containing the compound, wherein R is methyl, ethyl, propyl, vinyl or propenyl. The present invention also provides a crystalline form of the compound, a preparation method and use of the crystalline form, and a pharmaceutical composition comprising the crystalline form. The compounds having the structure of formula (I) of the present invention are present in a solid form, which not only can solve the problem of clopidogrel resistance, but also can solve the problem of severe hemorrhagic side effect and poor safety of some drugs, as well as the problem of poor stability of existing compounds. It can be developed into an ADP receptor antagonist antiplatelet agent with clear therapeutic effect, no resistance and better stability.

Abstract: The present invention provides a compound having a structure of formula (I), a preparation method and use thereof, and a pharmaceutical composition containing the compound, wherein R is methyl, ethyl, propyl, vinyl or propenyl. The present invention also provides a crystalline form of the compound, a preparation method and use of the crystalline form, and a pharmaceutical composition comprising the crystalline form. The compounds having the structure of formula (I) of the present invention are present in a solid form, which not only can solve the problem of clopidogrel resistance, but also can solve the problem of severe hemorrhagic side effect and poor safety of some drugs, as well as the problem of poor stability of existing compounds. It can be developed into an ADP receptor antagonist antiplatelet agent with clear therapeutic effect, no resistance and better stability.